<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Onyx Pharmaceuticals Inc. | Company News & Executive Profiles - ONXX | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Onyx Pharmaceuticals Inc.]]></description>
	<s:counts start="0" returned="10" found="25" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Onyx Pharmaceuticals: Could Acquiring Proteolix Be the Deal of the Year?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F168170-onyx-pharmaceuticals-could-acquiring-proteolix-be-the-deal-of-the-year%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Onyx&#8217;s ONXX stock decline in the past few months puzzled its shareholders. Nothing that has come in the news in the past year has been bad. On the contrary, a string of promising results was incessantly coming from the clinical trials of the firm&#8217;s cancer drug Nexavar on a variety...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Thu, 22 Oct 2009 09:16:42 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/prohost+biotech.html"><![CDATA[Prohost Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ONXX</category>
	</item>
	<item>
		<title><![CDATA[Onyx / Proteolix: Checking the Synergy of the Acquisition]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166218-onyx-proteolix-checking-the-synergy-of-the-acquisition%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Douglas Cress submits: Onyx Pharmaceuticals ONXX has agreed to purchase private biotechnology company Proteolix for $276 million in cash, Bloomberg reports. The acquisition will provide Onyx with a late-stage, next-generation therapy to treat multiple myeloma, a form of blood cancer that affects over 180,000 people worldwide. Shares in Onyx rose...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 13 Oct 2009 06:10:26 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/douglas+cress.html"><![CDATA[Douglas Cress]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ONXX</category>
	</item>
	<item>
		<title><![CDATA[Onyx to Acquire Cancer Drugmaker Proeolix]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F166200-onyx-to-acquire-cancer-drugmaker-proeolix%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   Recently, Onyx Pharmaceuticals ONXX announced that it will purchase privately held cancer drugmaker Proteolix for an upfront cash payment of $276 million. This transaction gives Onyx access to Proteolix's lead compound, carfilzomib, a mid-stage multiple myeloma drug. Apart from the upfront cash payment, Onyx, which currently...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 13 Oct 2009 05:07:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ONXX</category>
	</item>
	<item>
		<title><![CDATA[Bayer/Onyx Cancer Drug: Possible Additional Indication Looks Promising]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F163635-bayer-onyx-cancer-drug-possible-additional-indication-looks-promising%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   After releasing promising data from a mid-stage trial of regorafenib in kidney cancer, the company came out with impressive data on Nexavar for the treatment of breast cancer. Nexavar, which Bayer (BAYRY.PK) co-developed with Onyx Pharmaceuticals ONXX, is currently approved for liver and kidney cancers. Data...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Sun, 27 Sep 2009 05:08:18 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ONXX</category>
	</item>
	<item>
		<title><![CDATA[Onyx Pharmaceuticals: Is Nexavar the Next Avastin?]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F162749-onyx-pharmaceuticals-is-nexavar-the-next-avastin%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Nexavar, approved for kidney and lung cancer, is already a success by most measures.  It should reach blockbuster status, surpassing $1 billion in worldwide annual sales by 2010.  Most companies would be quite pleased to have a drug deliver such results, and Nexavar&#8217;s owners, Onyx Pharmaceuticals ONXX and...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 22 Sep 2009 06:54:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/raymond+chung.html"><![CDATA[Raymond Chung]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ONXX</category>
	</item>
	<item>
		<title><![CDATA[Onyx Signaling Appetite for Deals]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F155333-onyx-signaling-appetite-for-deals%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[EP Vantage submits: Onyx Pharmaceuticals ONXX ruffled some feathers last week by announcing a fundraising effort to raise around $300m, prompting shareholders to fret about what the already cash-rich company has planned. Vague talk about licensing opportunities by management, who refused to say what type of deals they were pursuing,...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 11 Aug 2009 03:03:47 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/ep+vantage.html"><![CDATA[EP Vantage]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ONXX</category>
	</item>
	<item>
		<title><![CDATA[Onyx Pharmaceuticals Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-328351.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. Operator instructions Our first question comes from Jim Birchenough from Barclays Capital. Please go ahead. Jim Birchenough &#8211; Barclays Capital Hi, guys and congratulations on the strong quarter. Just wondering if you could spent a moment previewing round, you are disappoint around business development and...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 04 Aug 2009 19:09:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/opportunity.html"><![CDATA[Opportunity]]></category>
		<category domain="http://resources.bnet.com/topic/transaction.html"><![CDATA[Transaction]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/business+development.html"><![CDATA[Business Development]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/strategic+planning.html"><![CDATA[Strategic Planning]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/management.html"><![CDATA[Management]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ONXX</category>
	</item>
	<item>
		<title><![CDATA[Onyx Pharmaceuticals Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F153790-onyx-pharmaceuticals-inc-q2-2009-earnings-call-transcript%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Onyx Pharmaceuticals Inc. ONXX   Q2 2009 Earnings Call Transcript   August 4, 2009 5:00 pm ET]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 04 Aug 2009 08:09:11 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ONXX</category>
	</item>
	<item>
		<title><![CDATA[Onyx Pharmaceuticals Inc. Q1 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-299746.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions We have our first question from Cory Kasimov from JP Morgan. Please go ahead. Mona Ashiya &#8211; JP Morgan  Hi, good afternoon. This is Mona for Cory. A couple of questions; last week when Bayer reported, you also reiterated Nexavar sales guidance and I...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 06 May 2009 18:34:18 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/japan.html"><![CDATA[Japan]]></category>
		<category domain="http://resources.bnet.com/topic/j.p.+morgan+chase+%2526+co..html"><![CDATA[J.P. Morgan Chase & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/region.html"><![CDATA[Region]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/asia-pacific.html"><![CDATA[Asia-Pacific]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JPM</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">JPM,ONXX</category>
	</item>
	<item>
		<title><![CDATA[Arena's Financing Deal with Azimuth Is a Healthy Move]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F127704-arena-s-financing-deal-with-azimuth-is-a-healthy-move%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Mark Cifra submits: Secondaries and convertibles are pretty common stuff to most biotech investors. That is why when I first read the news that Arena Pharmaceuticals ARNA signed an equity financing commitment deal for 50 million dollars, I figured it was the same old biotech secondary. Until I caught the...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Wed, 25 Mar 2009 01:15:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/mark+cifra.html"><![CDATA[Mark Cifra]]></category>
		<category domain="http://resources.bnet.com/topic/arena+pharmaceuticals+inc..html"><![CDATA[Arena Pharmaceuticals Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/onyx+pharmaceuticals+inc..html"><![CDATA[Onyx Pharmaceuticals Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ARNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ONXX</category>
		<category domain="tickers">ARNA,ONXX</category>
	</item>
</channel>
</rss>
